A federal jury ruled that Apple has to pay $634 million for infringing smartwatch patents

A federal jury has ordered Apple to pay Masimo $634 million for infringing on patents related to blood-oxygen tracking technology utilized in the Apple Watch's Workout and Heart Rate apps. Apple disputes the verdict, asserting the patent expired in 2022 and pertains to outdated technology, and plans to appeal the decision. This ruling marks a significant development in the protracted legal dispute between the two companies, which has previously resulted in temporary sales suspensions and feature redesigns for Apple's smartwatches.

Analysis

A federal jury has ordered Apple (AAPL) to pay Masimo (MASI) $634 million for infringing on patents related to blood-oxygen tracking technology utilized in the Apple Watch's Workout and Heart Rate apps. This ruling represents a significant financial liability for Apple and a substantial victory for Masimo, as reflected in the per-ticker sentiment scores of -0.7 for AAPL and +0.7 for MASI. Apple disputes the verdict, claiming the patent expired in 2022 and pertains to outdated technology, and intends to appeal the decision.

This verdict is part of a protracted and complex legal dispute between the two companies, which has previously led to temporary sales suspensions of Apple's Series 9 and Ultra 2 smartwatches. While the current ruling provides some closure on this specific California lawsuit, Apple and Masimo remain embroiled in multiple related legal actions. The ongoing litigation introduces continued uncertainty regarding Apple's intellectual property strategy and product features, particularly in the health monitoring space.

The moderately negative general sentiment (-0.5) and moderate market impact score (0.35) suggest that while the fine is notable, the market views it as a manageable, albeit unwelcome, development for Apple. However, the precedent set by this ruling could influence future patent disputes within the competitive wearable technology and health tech sectors. The outcome of Apple's appeal will be critical in determining the final financial and operational implications.

Key Decisions for Investors

• Monitor the progress of Apple's appeal, as the final financial impact and operational adjustments for the Apple Watch line remain uncertain.
• Assess the potential for increased litigation risk for technology companies operating in health-related fields, given the precedent set by this patent infringement ruling.
• Consider the long-term implications for Apple's health-tech strategy and intellectual property management, particularly if further redesigns or licensing agreements become necessary.